Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

Inclusion Criteria: Histologically or cytologically confirmed non-small cell lung carcinoma (NSCLC) meeting the following criteria: The following subtypes are eligible: Adenocarcinoma (including bronchoalveolar) Large cell carcinoma (including giant and clear cell carcinomas) Poorly differentiated carcinoma No squamous cell histology Unresectable stage II-III disease Tumor must not invade the trachea or major arterial or venous structures Measurable or evaluable disease Measurable disease defined as ? 1 lesion that can be accurately measured in ? 1 dimension as ? 20 mm with conventional techniques or as ? 10 mm with spiral CT scan No evidence of CNS disease, including primary brain tumor or brain metastases ECOG performance status (PS) 0-1 or Karnofsky PS 60-100% Life expectancy > 6 months Granulocyte count ? 1,500/mm³ Platelet count ? 100,000/mm³ Bilirubin < 1.25 times upper limit of normal (ULN) AST < 2.5 times ULN Creatinine normalOR creatinine clearance ? 60 mL/min FEV_1 ? 1.0 liters 24-hour urine protein < 1,000 mg (for patients with urine protein:creatinine ratio [by urine analysis] > 1.0) No hemoptysis within the past 12 months (defined as bright red blood in sputum of > 1 teaspoon) No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies No history of allergic reactions attributed to carboplatin or taxane No serious or nonhealing wound, ulcer, or bone fracture No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days No significant traumatic injury within the past 14 days No clinically significant cardiovascular disease, including any of the following: Cerebrovascular accident within the past 6 months Uncontrolled hypertension Myocardial infarction or unstable angina within the past 6 months New York Heart Association class II-IV congestive heart failure Serious cardiac arrhythmia requiring medication Unstable angina pectoris Clinically significant peripheral vascular disease No known bleeding diathesis or coagulopathy No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) No uncontrolled intercurrent illness including, but not limited to, the following: Ongoing or active infection Psychiatric illness or social situations that would limit study compliance Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for ? 6 months after completion of study treatment No HIV positivity No prior chemotherapy No prior epidermal growth factor receptor-targeted therapy No prior vascular endothelial growth factor-targeted therapy No prior chest radiotherapy No major surgery or open biopsy within the past 14 days No concurrent treatment with full-dose anticoagulation Low-dose anticoagulants (e.g., warfarin) to maintain patency of central venous catheter allowed provided all of the following criteria are met: Daily dose of warfarin < 1 mg INR < 1.5 No other concurrent investigational agents No concurrent major surgical procedures No other concurrent anticancer agents or therapies No concurrent chronic treatment with aspirin (> 325 mg daily) or nonsteroidal anti-inflammatory agents No dexamethasone as an antiemetic during chemoradiotherapy No colony-stimulating factors during chemoradiotherapy